For research use only. Not for therapeutic Use.
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively[1].
Vimseltinib is a c-FMS (CSF-IR) and c-Kit dual inhibitor with anti-cancer and anti-proliferative activities[1].
Catalog Number | I015466 |
CAS Number | 1628606-05-2 |
Synonyms | 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one |
Molecular Formula | C23H25N7O2 |
Purity | ≥95% |
InChI | InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27) |
InChIKey | TVGAHWWPABTBCX-UHFFFAOYSA-N |
SMILES | CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C |
Reference | [1]. Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2. |